Tasimelteon Patent Expiration
Tasimelteon is Used for treating nighttime sleep disturbances in Smith-Magenis syndrome and non-24-hour sleep-wake disorder with tasimelteon. It was first introduced by Vanda Pharmaceuticals Inc
Tasimelteon Patents
Given below is the list of patents protecting Tasimelteon, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Hetlioz | US10071977 | Highly purifid pharmaceutical grade tasimelteon | Feb 12, 2035 | Vanda Pharms Inc |
| Hetlioz | US10149829 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US10179119 | Method of treatment | Aug 29, 2035 | Vanda Pharms Inc |
| Hetlioz | US10376487 | Method of treatment | Jul 27, 2035 | Vanda Pharms Inc |
| Hetlioz | US10449176 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US10610510 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US10610511 | Method of treatment | Oct 10, 2034 | Vanda Pharms Inc |
| Hetlioz | US10829465 | Highly purified pharmaceutical grade tasimelteon | Feb 12, 2035 | Vanda Pharms Inc |
| Hetlioz | US10945988 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US10980770 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US11141400 | Method of treatment | Oct 10, 2034 | Vanda Pharms Inc |
| Hetlioz | US11266622 | Method of treatment | Aug 29, 2035 | Vanda Pharms Inc |
| Hetlioz | US11285129 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US11566011 | Highly purified pharmaceutical grade tasimelteon | Feb 12, 2035 | Vanda Pharms Inc |
| Hetlioz | US11633377 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US11759446 | Liquid tasimelteon formulations and methods of use thereof | Feb 21, 2041 | Vanda Pharms Inc |
| Hetlioz | US11760740 | Highly purified pharmaceutical grade tasimelteon | Feb 12, 2035 | Vanda Pharms Inc |
| Hetlioz | US11786502 | Method of treatment | Oct 10, 2034 | Vanda Pharms Inc |
| Hetlioz | US11826339 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US11833130 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US11850229 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US11918556 | Treatment of circadian rhythm disorders | Apr 07, 2033 | Vanda Pharms Inc |
| Hetlioz | US11918557 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US5856529 | Benzofuran and dihydrobenzofuran melatonergic agents |
Dec 09, 2022
(Expired) | Vanda Pharms Inc |
| Hetlioz | US8785492 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US9060995 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US9539234 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US9549913 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | US9730910 | Treatment of circadian rhythm disorders | May 17, 2034 | Vanda Pharms Inc |
| Hetlioz | US9855241 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz | USRE46604 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz Lq | US10071977 | Highly purifid pharmaceutical grade tasimelteon | Feb 12, 2035 | Vanda Pharms Inc |
| Hetlioz Lq | US10149829 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz Lq | US10179119 | Method of treatment | Aug 29, 2035 | Vanda Pharms Inc |
| Hetlioz Lq | US10376487 | Method of treatment | Jul 27, 2035 | Vanda Pharms Inc |
| Hetlioz Lq | US10610510 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz Lq | US10610511 | Method of treatment | Oct 10, 2034 | Vanda Pharms Inc |
| Hetlioz Lq | US10829465 | Highly purified pharmaceutical grade tasimelteon | Feb 12, 2035 | Vanda Pharms Inc |
| Hetlioz Lq | US10980770 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz Lq | US11141400 | Method of treatment | Oct 10, 2034 | Vanda Pharms Inc |
| Hetlioz Lq | US11202770 | Liquid tasimelteon formulations and methods of use thereof | Dec 11, 2040 | Vanda Pharms Inc |
| Hetlioz Lq | US11266622 | Method of treatment | Aug 29, 2035 | Vanda Pharms Inc |
| Hetlioz Lq | US11285129 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz Lq | US11566011 | Highly purified pharmaceutical grade tasimelteon | Feb 12, 2035 | Vanda Pharms Inc |
| Hetlioz Lq | US11633377 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz Lq | US11759446 | Liquid tasimelteon formulations and methods of use thereof | Feb 21, 2041 | Vanda Pharms Inc |
| Hetlioz Lq | US11760740 | Highly purified pharmaceutical grade tasimelteon | Feb 12, 2035 | Vanda Pharms Inc |
| Hetlioz Lq | US11786502 | Method of treatment | Oct 10, 2034 | Vanda Pharms Inc |
| Hetlioz Lq | US11826339 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz Lq | US11833130 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz Lq | US11850229 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz Lq | US11918556 | Treatment of circadian rhythm disorders | Apr 07, 2033 | Vanda Pharms Inc |
| Hetlioz Lq | US11918557 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz Lq | US5856529 | Benzofuran and dihydrobenzofuran melatonergic agents |
Dec 09, 2022
(Expired) | Vanda Pharms Inc |
| Hetlioz Lq | US9539234 | Treatment of circadian rhythm disorders | Jan 25, 2033 | Vanda Pharms Inc |
| Hetlioz Lq | US9730910 | Treatment of circadian rhythm disorders | May 17, 2034 | Vanda Pharms Inc |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Tasimelteon Generics
Several generic applications have been filed for Tasimelteon. The first generic version for Tasimelteon was by Teva Pharmaceuticals Usa Inc and was approved on Dec 12, 2022. And the latest generic version is by Msn Laboratories Private Ltd and was approved on Jan 12, 2023.
Given below is the list of companies who have filed for Tasimelteon generic.
1. TEVA PHARMS USA INC
Teva Pharmaceuticals Usa Inc has filed for 1 generic for Tasimelteon. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 20MG | capsule | Prescription | ORAL | AB | Dec 12, 2022 |
2. APOTEX
Apotex Inc has filed for 1 generic for Tasimelteon. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 20MG | capsule | Prescription | ORAL | AB | Dec 20, 2022 |
3. MSN
Msn Laboratories Private Ltd has filed for 1 generic for Tasimelteon. Given below are the details of the strengths of this generic introduced by Msn.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 20MG | capsule | Prescription | ORAL | AB | Jan 12, 2023 |